Construction and biological properties of yellow fever 17D/dengue type 1 recombinant virus

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 101, Issue 3, 2007, Pages 289-298

  Mateu, G P ^a,b   Marchevsky, R S ^c   Liprandi, F ^b   Bonaldo, M C ^a   Coutinho, E S F ^a   Dieudonne M ^b   Caride, E ^c   Jabor, A V ^c   Freire, M S ^c   Galler, R ^a,c  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^c Instituto de Technologia em Imunobiologicos   (Brazil)

Author keywords

Attenuation; Dengue; Envelope gene; Vaccine; Yellow fever

Indexed keywords

CHIMERIVAX; COMPLEMENTARY DNA; DENGUE VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS RNA; YELLOW FEVER VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIMERA; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; ENVELOPE GENE; ESCHERICHIA COLI; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LETHALITY; MALE; MOLECULAR CLONING; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PLAQUE FORMING CELL; RHESUS MONKEY; RNA TRANSCRIPTION; STRAIN DIFFERENCE; VACCINE PRODUCTION; VERO CELL; VIRUS ATTENUATION; VIRUS ENCEPHALITIS; VIRUS ENVELOPE; VIRUS GENE; VIRUS ISOLATION; VIRUS RECOMBINANT; VIRUS STRAIN; VIRUS VIRULENCE; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CERCOPITHECUS AETHIOPS; DENGUE VACCINES; DENGUE VIRUS; GENES, VIRAL; MICE; MOLECULAR SEQUENCE DATA; REASSORTANT VIRUSES; RECOMBINATION, GENETIC; TRANSFECTION; VACCINES, ATTENUATED; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRULENCE; YELLOW FEVER VIRUS;

DENGUE VIRUS; ESCHERICHIA COLI; FLAVIVIRUS; MACACA MULATTA; MUS;

EID: 33846010764     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2006.08.006     Document Type: Article

References (47)

1. Angsubhakorn S., Yoksan S., Bhamarapravati N., Moe J.B., Marchette N.J., Pradermwong A., and Sahaphong S. Dengue-4 vaccine: neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys. Trans. R. Soc. Trop. Med. Hyg. 82 (1988) 746-749
2. Angsubhakorn S., Yoksan S., Pradermwong A., Nitatpattana N., Sahaphong S., and Bhamarapravati N. Dengue-3 (16562) PGMK 33 vaccine: neurovirulence, viremia and immune responses in Macaca fascicularis. Southeast Asian J. Trop. Med. Public Health 25 (1994) 554-559
3. Bonaldo M.C., Garratt R.C., Caufour P.S., Freire M.S., Rodrigues M.M., Nussenzweig R.S., and Galler R. Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus. J. Mol. Biol. 315 (2002) 873-885
4. Burke D.S., and Monath T.P. Flaviviruses. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. fourth ed. (2001), Lippincott Williams & Wilkins, Philadelphia, PA 1049-1125
5. Burke D.S., Nisalak A., and Johnston D.E. A prospective study of dengue infections in Bangkok. Am. J. Trop. Med. Hyg. 38 (1988) 172-180
6. Calisher C.H., Karabatsos N., Dalrymple J.M., Shope R.E., Porterfield J.S., Westaway E.G., and Brandt W.E. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antiserum. J. Gen. Virol. 70 (1989) 37-43
7. Caufour P.S., Motta M.C.A., Yamamura A.M.Y., Vazquez S., Ferreira I.I., Jabor A.V., Bonaldo M.C., Freire M.S., and Galler R. Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses. Virus Res. 79 (2001) 1-14
8. Durbin A.P., Karron R.A., Sun W., Vaughn D.W., Reynolds M.J., Perreault J.R., Thumar B., Men R., Lai C.J., Elkins W.R., Chanock R.M., Murphy B.R., and Whitehead S.S. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am. J. Trop. Med. Hyg. 65 (2001) 405-413
9. Edelman R., Wasserman S.S., Bodison S.A., Putnak R.J., Eckels K.H., Tang D., Kanesa-Thasan N., Vaughn D.W., Innis B.L., and Sun W. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am. J. Trop. Med. Hyg. 69 (2004) 48-60
10. Galler R., Pugachev K.V., Santos C.L., Ocran S.W., Jabor A.V., Rodrigues S.G., Marchevsky R.S., Freire M.S., Almeida L.F., Cruz A.C., Yamamura A.M., Rocco I.M., da Rosa E.S., Souza L.T., Vasconcelos P.F., Guirakhoo F., and Monath T.P. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 290 (2001) 309-319
11. Goncalvez A.P., Escalante A.A., Pujol F.H., Ludert J.E., Tovar D., Salas R.A., and Liprandi F. Diversity and evolution of the envelope gene of dengue virus type 1. Virology 303 (2002) 110-119
12. Guirakhoo F., Arroyo J., Pugachev K.V., Miller C., Zhang Z.X., Weltzin R., Georgakopoulos K., Catalan J., Ocran S., Soike K., Ratterree M., and Monath T.P. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 75 (2001) 7290-7304
13. Guirakhoo F., Pugachev K., Arroyo J., Miller C., Zhang Z.X., Weltzin R., Georgakopoulos K., Catalan J., Ocran S., Draper K., and Monath T.P. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298 (2002) 146-159
14. Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., Lang J., Ocran S., Mitchell F., Parsons M., Brown N., Brandler S., Fournier C., Barrere B., Rizvi F., Travassos A., Nichols R., Trent D., and Monath T.P. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 78 (2004) 4761-4775
15. Guirakhoo F., Zhang Z., Myers G., Johnson B.W., Pugachev K., Nichols R., Brown N., Levenbook I., Draper K., Cyrek S., Lang J., Fournier C., Barrere B., Delagrave S., and Monath T.P. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J. Virol. 78 (2004) 9998-10008
16. Halstead S.B. Pathogenesis of dengue: challenges to molecular biology. Science 239 (1988) 476-481
17. Huang C.Y., Butrapet S., Pierro D.J., Chang G.J., Hunt A.R., Bhamarapravati N., Gubler D.J., and Kinney R.M. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J. Virol. 74 (2000) 3020-3028
18. Hommel D., Talarmin A., Deubel V., Reynes J.M., Drouet M.T., Sarthou J.L., and Hulin A. Dengue encephalitis in French Guiana. Res. Virol. 149 (1998) 235-238
19. Johnson A.L., Guirakhoo F., and Roehrig J.T. The envelope glycoproteins of dengue 1 and dengue 2 viruses grown in mosquito cells differ in their utilization of potential glycosylation sites. Virology 203 (1994) 241-249
20. Kanesa-Thasan N., Sun W., Kim-Ahn G., Van Albert S., Putnak J.R., King A., Raengsakulsrach B., Christ-Schmidt H., Gilson K., Zahradnik J.M., Vaughn D.W., Innis B.L., Saluzzo J.F., and Hoke C.H. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19 (2001) 3179-3188
21. Kanesa-Thasan N., Edelman R., Tacket C.O., Wasserman S.S., Vaughn D.W., Coster T.S., Kim-Ahn G.J., Dubois D.R., Putnak J.R., King A., Summers P.L., Innis B.L., Eckels K.H., and Hoke Jr. C.H. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am. J. Trop. Med. Hyg. 69 (2003) 17-23
22. Kliks S.C., Nisalak A., Brandt W.E., Wahl L., and Burke D.S. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40 (1989) 444-451
23. Lai C.J., and Monath T.P. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv. Virus Res. 61 (2003) 469-509
24. Leao R.N., Oikawa T., Rosa E.S., Yamaki J.T., Rodrigues S.G., Vasconcelos H.B., Sousa M.R., Tsukimata J.K., Azevedo R.S., and Vasconcelos P.F. Isolation of dengue 2 virus from a patient with central nervous system involvement (transverse myelitis). Rev. Soc. Bras. Med. Trop. 35 (2002) 401-404
25. Levenbook I.S., Pelleu L.J., and Elisberg B.L. The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination. J. Biol. Stand. 15 (1987) 305-313
26. Lum L.C., Lam S.K., Choy Y.S., George R., and Harun F. Dengue encephalitis: a true entity?. Am. J. Trop. Med. Hyg. 54 (1996) 256-259
27. Marchevsky R.S., Freire M.S., Coutinho E.S., and Galler R. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys. Virology 316 (2003) 55-63
28. Marchevsky R.S., da Luz Leal M., Homma A., Coutinho E.S., Camacho L.A., Jabor A.V., Galler R., and Freire M.S. Molecular and phenotypic analysis of a working seed lot of yellow fever virus 17DD vaccine strain produced from the secondary seed lot 102/84 with an additional passage in chicken embryos. Biologicals 34 (2006) 191-197
29. Modis Y., Ogata S., Clements D., and Harrison S.C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 6986-6991
30. Monath T.P. Yellow Fever Vaccine. fourth ed. (2003), W.B. Saunders Company, Philadelphia, PA
31. Nathanson N., Davis M., Thind I.S., and Price W.H. Histological studies of the monkey neurovirulence of group B arboviruses. II. Selection of indicator centers. Am. J. Epidemiol. 84 (1966) 524-540
32. Nuegoonpipat A., Berlioz-Arthaud A., Chow V., Endy T., Lowry K., Mai le Q., Ninh T.U., Pyke A., Reid M., Reynes J.M., SuYun S.T., Thu H.M., Wong S.S., Holmes E.C., and Aaskov J. Sustained transmission of dengue virus type 1 in the Pacific due to repeated introductions of different Asian strains. Virology 329 (2004) 505-512
33. Post P.R., Santos C.N.D., Carvalho R., Cruz A.C.R., Rice C.M., and Galler R. Heterogeneity in envelope protein sequence and N-linked glycosylation among yellow fever virus vaccine strains. Virology 188 (1992) 160-167
34. Pugachev K.V., Guirakhoo F., Ocran S.W., Mitchell F., Parsons M., Penal C., Guirakhoo S., Pougatcheva S.O., Arroyo J., Trent D.W., and Monath T.P. High fidelity of yellow fever virus RNA polymerase. J. Virol. 78 (2004) 1032-1038
35. Rice C.M. Flaviviridae: the viruses and their replication. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Fields Virology (1996), Lippincott-Raven Publishers, Philadelphia, New York 931-959
36. Rice C.M., Grakoui A., Galler R., and Chambers T.J. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by 'in vitro' ligation. New Biol. 1 (1989) 285-296
37. Rico-Hesse R. Microevolution and virulence of dengue viruses. Adv. Virus Res. 59 (2003) 315-341
38. Rigau-Perez J.G., Clark G.G., Gubler D.J., Reiter P., Sanders E.J., and Vorndam A.V. Dengue and dengue hemorrhagic fever. Lancet 352 (1998) 971-977
39. Rothman A.L. Viral pathogenesis of dengue infection. In: Gubler D.J., and Kuno G. (Eds). Dengue and Dengue Hemorrhagic Fever (1997), CAB International, New York, NY 245-271
40. Ruggli N., Tratschin J.D., Mittelholzer C., and Hofmann M.A. Nucleotide sequence of classical swine fever virus strain Alfort/187 and transcription of infectious RNA from stably cloned full-length cDNA. J. Virol. 70 (1996) 3478-3487
41. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., Sirivichayakul C., Pengsaa K., Pojjaroen-Anant C., Chokejindachai W., Jagsudee A., Saluzzo J.F., and Bhamarapravati N. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am. J. Trop. Med. Hyg. 66 (2002) 264-272
42. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., Sirivichayakul C., Pengsaa K., Pojjaroen-Anant C., Chambonneau L., Saluzzo J.F., and Bhamarapravati N. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr. Infect. Dis. J. 23 (2004) 99-109
43. Saluzzo J.F. Empirically derived live-attenuated vaccines against dengue and Japanese encephalitis. Adv. Virus Res. 61 (2003) 419-443
44. Sun W., Edelman R., Kanesa-Thasan N., Eckels K.H., Putnak J.R., King A.D., Houng H.S., Tang D., Scherer J.M., Hoke Jr. C.H., and Innis B.L. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am. J. Trop. Med. Hyg. 69 (2003) 24-31
45. WHO, 1998. Requirements for yellow fever vaccine. World Health Organization, Geneva, Technical Report Series No. 872, pp. 31-68.
46. WHO, 2002. Dengue and dengue haemorrhagic fever. Geneva, World Health Organization, Fact sheet No. 117.
47. Zhang W., Chipman P.R., Corver J., Johnson P.R., Zhang Y., Mukhopadhyay S., Baker T.S., Strauss J.H., Rossmann M.G., and Kuhn R.J. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat. Struct. Biol. 10 (2003) 907-912